共 50 条
- [1] Alepro: a phase II, multicentre, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancerINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A350 - A350Ottenbourgs, TineVan Gorp, ToonKridelka, FredericBaert, ThaisDenys, HanneloreSelle, FredericBaas, IngeVan Rompuy, Anne-SophieLambrechts, DietherVan Nieuwenhuysen, Els
- [2] A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trialINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (04) : 627 - 630Ottenbourgs, Tinevan Gorp, ToonKridelka, FredericBaert, ThaisDenys, HanneloreSelle, FredericBaas, IngeVan Rompuy, Anne-SophieLambrechts, DietherVan Nieuwenhuysen, Els
- [3] A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial CancerJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 599 - +Konstantinopoulos, Panagiotis A.Lee, Elizabeth K.Xiong, NiyaKrasner, CarolynCampos, SusanaKolin, David L.Liu, Joyce F.Horowitz, NeilWright, Alexi A.Bouberhan, SaraPenson, Richard T.Yeku, OladapoBowes, BrittanyNeedham, HopeHayes, MartinSawyer, HannahPolak, MadelineShea, MeghanCheng, Su-ChunCastro, CesarMatulonis, Ursula A.
- [4] Is Letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer?GYNECOLOGICAL ENDOCRINOLOGY, 2013, 29 (11) : 993 - 996Revelli, A.Porcu, E.Setti, P. E. LeviDelle Piane, L.Merlo, D. F.Anserini, P.
- [5] Neoadjuvant Chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI)CANCERS, 2024, 16 (18)Chae, HeejungSim, Sung HoonKwon, YoungmiLee, Eun-GyeongHan, Jai HongJung, So-YounLee, SeeyounKang, Han-SungKim, Yeon-JooKim, Tae HyunLee, Keun Seok
- [6] Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast CancerJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) : 2630 - 2637Baselga, JoseSemiglazov, Vladimirvan Dam, PeterManikhas, AlexeyBellet, MeritxellMayordomo, JoseCampone, MarioKubista, ErnstGreil, RichardBianchi, GiuliaSteinseifer, JuttaMolloy, BettyTokaji, ErikaGardner, HumphreyPhillips, PennyStumm, MichaelLane, Heidi A.Dixon, J. MichaelJonat, WalterRugo, Hope S.
- [7] Phase II study of letrozole in estrogen receptor (ER) positive relapsed epithelial ovarian cancer (EOC).JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 261S - 261SGourlev, C.Smyth, J. F.Mackean, M.Stevenson, A.Williams, A.Rye, T.Reed, N.Vasey, P.Gabra, H.Langdon, S.
- [8] A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast CancerCLINICAL CANCER RESEARCH, 2020, 26 (20) : 5310 - 5319Tolaney, Sara M.Sahebjam, SolmazLe Rhun, EmilieBachelot, ThomasKabos, PeterAwada, AhmadYardley, DeniseChan, ArleneConte, PierfrancoDieras, VeroniqueLin, Nancy U.Bear, MelissaChapman, Sonya C.Yang, ZhengyuChen, YanyunAnders, Carey K.
- [9] A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancerGYNECOLOGIC ONCOLOGY, 2010, 119 (01) : 32 - 37Friedlander, MichaelHancock, Kenneth C.Rischin, DannyMessing, Mark J.Stringer, Claude A.Matthys, Gemma M.Ma, BoHodge, Jeffrey P.Lager, Joanne J.
- [10] Antiestrogen therapy is active in selected ovarian cancer cases: The use of letrozole in estrogen receptor-positive patientsCLINICAL CANCER RESEARCH, 2007, 13 (12) : 3617 - 3622Smyth, John F.Gourley, CharlieWalker, GraemeMacKean, Melanie J.Stevenson, AlanWilliams, Alistair R. W.Al Nafussi, AwatifRye, TzyviaRye, RonStewart, MoiraMcCurdy, JanetMano, MaxReed, NickMcMahon, TraceyVasey, PaulGabra, HaniLangdon, Simon P.